Novo, the Danish pharmaceutical company behind blockbuster drugs such as Wegovy and Ozempic, has reduced its global workforce by around 13,000 over the past year as it cuts costs and redirects resources towards new growth opportunities.
The workforce reduction comes at a challenging time for the company, which is facing intensifying competition in the obesity-drug market and preparing for future patent expirations affecting some of its biggest medicines.
13,000 Employees Have Left
Novo initially announced plans to reduce its workforce by around 9,000 positions last year as part of a major restructuring programme.
The company has now disclosed that its workforce has fallen by a total of around 13,000 over the past year.
The additional 4,000 departures include employees who left through natural attrition as well as positions that the company decided not to refill.
Novo’s global workforce now stands at around 67,000 employees.
Why Is Novo Cutting Jobs?
The restructuring is designed to simplify the organisation, improve efficiency and redirect more resources towards research and development.
Novo is facing increasing competition in the fast-growing weight-loss drug market, particularly from US rival Eli Lilly.
Its blockbuster obesity medicines have generated enormous growth in recent years, but the company now wants to diversify its pipeline and reduce its dependence on a relatively small number of major products.
Wegovy Faces Growing Competition
Wegovy has been one of Novo’s biggest growth drivers, but competition in the obesity treatment market is becoming increasingly intense.
Eli Lilly’s competing medicines have gained significant ground, putting pressure on Novo to develop the next generation of treatments.
Novo is also facing future patent expirations for semaglutide, the active ingredient in Wegovy and Ozempic, making the development of new medicines increasingly important.
Novo Plans More Than Five Blockbusters
CEO Mike Doustdar has outlined an ambitious growth strategy for the coming years.
Novo aims to launch more than five medicines capable of generating blockbuster-level sales by 2030.
The company is also targeting more than 150 billion Danish kroner in sales from its future drug pipeline by 2035.
The strategy includes expanding beyond diabetes and obesity into areas such as liver disease, cardiovascular health and other speciality treatments.
More Money For Research And Development
The workforce reduction is part of a broader effort to redirect resources towards research and development.
Novo plans to accelerate the number of drug programmes entering human clinical trials, while also considering targeted acquisitions and partnerships to strengthen its pipeline.
The company is also continuing to invest in manufacturing capacity as it prepares for increased demand for newer treatments.
Betting On Next-Generation Obesity Drugs
Novo is continuing to develop new obesity treatments, including CagriSema and other experimental medicines.
The company is also expanding its focus on oral obesity treatments, which could provide another growth avenue as demand for weight-loss medicines continues to increase.
Novo expects to significantly expand the number of patients it serves globally over the coming years.
A Major Reset For The Drugmaker
The 13,000 reduction represents a major change for a company that expanded rapidly during the global boom in diabetes and obesity treatments.
Novo is now attempting to operate with a leaner workforce while putting greater resources into its research pipeline and future medicines.
The company’s strategy will depend heavily on whether its new treatments can offset intensifying competition and the eventual loss of exclusivity for some of its existing blockbuster drugs.
Summary
Novo has reduced its global workforce by around 13,000 over the past year as the pharmaceutical giant cuts costs and redirects resources towards research and new medicines. Facing growing competition in the obesity-drug market and future patent expirations, the company aims to launch more than five blockbuster-level medicines by 2030 while expanding into new treatment areas.iurce
